These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 35537758)

  • 1. Editorial Comment from Dr Yuasa to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
    Yuasa T
    Int J Urol; 2022 Jul; 29(7):740. PubMed ID: 35537758
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial Comment from Dr Kobayashi to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
    Kobayashi T
    Int J Urol; 2022 Jul; 29(7):739. PubMed ID: 35478200
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
    Togashi K; Hatakeyama S; Yoneyama T; Hamaya T; Narita T; Fujita N; Iwamura H; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
    Int J Urol; 2022 Jul; 29(7):733-739. PubMed ID: 35362143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.
    Fonseca MHG; Pinto ACMD; Silva MFS; de Melo ACL; Vasconcelos GS; Dos Santos ER; de Carvalho Araújo FM; de Andrade LOM
    Emerg Infect Dis; 2022 Jun; 28(6):1237-1240. PubMed ID: 35421324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BNT162b2 mRNA COVID-19 Vaccine: First Approval.
    Lamb YN
    Drugs; 2021 Mar; 81(4):495-501. PubMed ID: 33683637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
    Robertson JFR; Sewell HF; Stewart M
    Lancet; 2021 Mar; 397(10277):879-880. PubMed ID: 33617766
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection.
    Wolff MJ; Acevedo ML; Núñez MA; Lafourcade M; Gaete-Argel A; Soto-Rifo R; Valiente-Echeverría F
    J Travel Med; 2022 May; 29(3):. PubMed ID: 35134229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
    Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
    N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors affecting the serologic response to SARS-CoV-2 vaccination in patients with solid tumors: A prospective study.
    Erdoğan AP; Ekinci F; Akçalı S; Göksel G
    J Infect Chemother; 2022 Sep; 28(9):1310-1316. PubMed ID: 35701330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.
    Haller MC; Kaiser RA; Langthaler S; Brandstetter C; Apfalter P; Kerschner H; Cejka D
    Transpl Int; 2021; 35():10026. PubMed ID: 35185359
    [No Abstract]   [Full Text] [Related]  

  • 12. More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    Taytard J; Prevost B; Corvol H
    N Engl J Med; 2022 Mar; 386(12):1191-1192. PubMed ID: 35235722
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study: authors' response.
    Shasha D; Heymann AD; Zacay G
    Clin Microbiol Infect; 2022 Mar; 28(3):454-455. PubMed ID: 34923127
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunogenicity of a BNT162b2 vaccine booster in health-care workers.
    Saiag E; Goldshmidt H; Sprecher E; Ben-Ami R; Bomze D
    Lancet Microbe; 2021 Dec; 2(12):e650. PubMed ID: 34661180
    [No Abstract]   [Full Text] [Related]  

  • 15. Disseminated herpes zoster in an immune-competent patient after SARS-CoV-2 vaccine (BNT162b2 Comirnaty, Pfizer).
    Zengarini C; Misciali C; Ferrari T; Dika E; La Placa M; Piraccini BM; Baraldi C
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e622-e623. PubMed ID: 35429051
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19.
    Cha HH; Lim SY; Kwon JS; Kim JY; Bae S; Jung J; Kim SH
    Korean J Intern Med; 2022 Mar; 37(2):455-459. PubMed ID: 35272444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
    Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response.
    Tychala A; Meletis G; Katsimpourlia E; Gkeka I; Dimitriadou R; Sidiropoulou E; Skoura L
    Hum Vaccin Immunother; 2021 Dec; 17(12):5148-5149. PubMed ID: 34714711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.